These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20465315)

  • 1. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
    Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
    Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
    Lybrand S; Wonder M
    Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
    Turkstra E; Bettington E; Donohue ML; Mervin MC
    Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications.
    Haque MM; Gumbie M; Gu M; Dissanayake G
    Aust Health Rev; 2023 Apr; 47(2):139-147. PubMed ID: 36543249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of sponsor hearings on health technology assessment decision making.
    Flowers M; Lybrand S; Wonder M
    Aust Health Rev; 2020 Apr; 44(2):258-262. PubMed ID: 31072455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
    Wonder MJ; Neville AM; Parsons R
    Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
    Robertson J; Walkom EJ; Bevan MD; Newby DA
    BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between financial impact and coverage of drugs in Australia.
    Mauskopf J; Chirila C; Masaquel C; Boye KS; Bowman L; Birt J; Grainger D
    Int J Technol Assess Health Care; 2013 Jan; 29(1):92-100. PubMed ID: 23217275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.